An interventional study of 6 sessions of adapted physical activity after stem cell transplant in Haematological Malignancy, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-30.
Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Hematologic Neoplasms with a site in France — 49 open to participants now, 58 under way, 5 of them phase 3. Hematologic Neoplasms · France.
Among the 142 studies in Hematologic Neoplasms with a site in France, this one is the 68th largest by planned enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2022, is one of 29 with no phase, reaches primary completion later than 17 of the 57 other live ones, and was the 102nd registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →49 of the 142 studies in Hematologic Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Annecy Genevois · Sites in France
Ages 18+
CSL Behring · Sites in France, United States, Belgium and 8 more countries
Ages 18+
Institut Paoli-Calmettes · Sites in France
Ages 18+
Quetzal Therapeutics · Sites in France, United States, Italy and 2 more countries
Ages 18–71
Janssen Research & Development, LLC · Sites in France, United States, Australia and 4 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 42 · Phase 3 16 · Phase 4 3
First in 2002; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 106 across the 107 interventional studies, 249 across the 35 observational. Of the 65 that completed or were terminated, 14 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 142 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nice is the lead sponsor of 725 studies on the registry; 177 are open to participants now.
Centre Hospitalier Universitaire de Nice has 4 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Hematologic Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT06350994Assistance Publique - Hôpitaux de ParisEarly Assessment of Cardiac Function After Treatment With CAR-T Cells | 2026-12 |
| NCT05379738Centre Hospitalier Universitaire de NiceImpact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy | 2026-12-10 |
| NCT02074839Institut de Recherches Internationales ServierStudy of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | 2026-12-31 |
| NCT05828459Onward TherapeuticsFirst-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | 2027-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 142 studies in Hematologic Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
It is a study about adaptated physical activity for patients receiving a stem cell transplantation. They will benefit of 6 adaptated individuals lessons at home between 1 month and 3 months after stem cell transplantation. The study's goal is to observe if adaptated activity has an positive impact on weight loss and on life quality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non inclusion criteria :
Exclusion criteria
6 sessions of physical activity
Other: 6 sessions of adapted physical activity after stem cell transplant
physical assessement before and after stem cell transplant: * weight loss * brachial muscle circumference * grip strength evaluation * short physical battery test psychometric assessment before and after stem cell transplant: * quality of life questionary * physical activities questionary
weight loss
Body weight n in kilograms
Time frame: before stem cell transplantation, 1 month , 3 months, 1 year after stem cell transplantation
weight loss
Calculation of the percent of body weight loss between the " before stem cell transplantation evaluation " and each evaluation after stem cell transplantation and after adaptated physical activity sessions.
Time frame: before stem cell transplantation, 1 month , 3 months, 1 year after stem cell transplantation
patient's ability to attend the classes
number of adaptated physical activity lessons attended by each patient after stem cell transplantation, calculation of feasibility
Time frame: 3 months after stem cell transplantation
body mass index
Measure of weight and height to evaluate the nutriotional status of a patient
Time frame: before stem cell transplantation, 1 month , 3 months, 1 year after stem cell transplantation
brachial muscle circumference
evaluation in centimeters of the brachial circumference to evaluate the evolution of the muscle circumference after stem cell transplantation and adaptated physical activity compared to the evaluation before stem cell transplantation. Using a measuring tape
Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation
grip strength evaluation
it is a measure of muscular strength
Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation
short physical battery test
it is a series of 3 physical tests to evaluate mobility the first test is a balance test (4 points), the second test is an evaluation of a walking speed (4 points) and the third test is a Chair rise test (4 points) The global test is on 12 points (12 is the better score)
Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation
Quality of Life Questionary C30 (QLQ-C30)
it is a score to evaluate the quality of life of patients facing illness The subscales scores are transformed to a 0 to 100 scale, with higher score on functionnal scales indicating better function and higher scores on sumptom scales indicating worse symptoms
Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation
in house developped physical activities questionary
it is a questionnary created especially for this study to evaluate on each step the capacity of each patient to maintain physical activities (social activities, autonomy at home for cooking and hygiene care, autonomy for transport to go to hospital appointments)
Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation
Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.
Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 54 months is above that.
Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nice →